Erratum: Outcomes of Dabigatran and Warfarin for Atrial Fibrillation (Annals of Internal Medicine (2017) 167 (845-854) DOI: 10.7326/M16-1157);Outcomes of dabigatran and warfarin for atrial fibrillation in contemporary practice

Annals of Internal Medicine

Volumn 167, Issue 12, 2017, Pages 845-854

  Go, Alan S ^a   Singer, Daniel E ^b   Toh, Sengwee ^c   Craig Cheetham, T ^d   Reichman, Marsha E ^e   Graham, David J ^e   Southworth, Mary Ross ^e   Zhang, Rongmei ^e   Izem, Rima ^e   Goulding, Margie R ^e   Houstoun, Monika ^e   Mott, Katrina ^e   Sung, Sue Hee ^a   Gagne, Joshua J ^f  

^a KAISER PERMANENTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD PILGRIM HEALTH CARE INSTITUTE   (United States)

^d WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN;

ACUTE HEART INFARCTION; AGE; AGED; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COHORT ANALYSIS; DRUG USE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; INCIDENCE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; MIDDLE AGED; PROPENSITY SCORE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; DABIGATRAN; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPENSITY SCORE; RETROSPECTIVE STUDIES; STROKE; WARFARIN;

EID: 85038589344     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/L18-0377     Document Type: Erratum

References (40)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-5.
2. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119-25.
3. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A metaanalysis. Ann Intern Med. 1999;131:492-501.
4. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e531S-e575S. doi:10.1378/chest.11-2304
5. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003;290:2685-92.
6. U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products-Pradaxa (dabigatran etexilate mesylate) capsules. 2010. Accessed at www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=022512 on 6 October 2017.
7. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. doi:10.1056/NEJMoa 0905561
8. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial [Letter]. N Engl J Med. 2010;363:1875-6. doi:10.1056/NEJMc 1007378
9. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-Analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172:397-402. doi:10.1001/archinternmed.2011.1666
10. Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-Analysis. Circulation. 2015;132:194-204. doi:10.1161/CIRCULATION AHA.114.013267
11. Lauw MN, Eikelboom JW, Coppens M, Wallentin L, Yusuf S, Ezekowitz M, et al. Effects of dabigatran according to age in atrial fibrillation. Heart. 2017;103:1015-1023. doi:10.1136/heartjnl-2016-310358
12. Legrand M, Mateo J, Aribaud A, Ginisty S, Eftekhari P, Huy PT, et al. The use of dabigatran in elderly patients. Arch Intern Med. 2011;171:1285-6. doi:10.1001/archinternmed.2011.314
13. Curtis LH, Weiner MG, Boudreau DM, Cooper WO, Daniel GW, Nair VP, et al. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:23-31. doi:10.1002/pds.2336
14. Forrow S, Campion DM, Herrinton LJ, Nair VP, Robb MA, Wilson M, et al. The organizational structure and governing principles of the Food and Drug Administration's Mini-Sentinel pilot program. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:12-7. doi:10.1002/pds.2242
15. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368:1272-4. doi:10.1056/NEJMp1302834
16. Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015;350:h1857. doi:10.1136/bmj.h1857
17. Hernandez I, Baik SH, Pinera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175:18-24. doi:10.1001/jamainternmed.2014.5398
18. Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjøth F, Rosenzweig M, Lip GY. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med. 2014;127:650-656.e5. doi:10.1016/j.amjmed.2014.01.031
19. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjøth F, Lane DA, Lip GY. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: A nationwide cohort study. Am J Med. 2014;127:1172-8.e5. doi:10.1016/j.amjmed.2014.07.023
20. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjøth F, Rosenzweig M, Lane DA, et al. Myocardial ischemic events in real world patients with atrial fibrillation treated with dabigatran or warfarin. Am J Med. 2014;127:329-336.e4. doi:10.1016/j.amjmed.2013.12.005
21. Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: A retrospective cohort study. J Am Heart Assoc. 2015;4. doi: 10.1161/JAHA.115.001798
22. Smythe MA, Forman MJ, Bertran EA, Hoffman JL, Priziola JL, Koerber JM. Dabigatran versus warfarin major bleeding in practice: An observational comparison of patient characteristics, management and outcomes in atrial fibrillation patients. J Thromb Thrombolysis. 2015;40:280-7. doi:10.1007/s11239-015-1213-7
23. Yap LB, Eng DT, Sivalingam L, Rusani BI, Umadevan D, Muhammad Z, et al. A comparison of dabigatran with warfarin for stroke prevention in atrial fibrillation in an Asian population. Clin Appl Thromb Hemost. 2016;22:792-797.
24. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157-64. doi:10.1161/CIRCULATIONAHA.114.012061
25. Avgil Tsadok M, Jackevicius CA, Rahme E, Humphries KH, Pilote L. Sex differences in dabigatran use, safety, and effectiveness in a population-based cohort of patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2015;8:593-9. doi:10.1161/CIRCOUTCOMES.114.001398
26. Avgil-Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Behlouli H, et al. Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost. 2016;115:152-60. doi:10.1160/TH15-03-0247
27. McGraw D, Rosati K, Evans B. A policy framework for public health uses of electronic health data. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:18-22. doi:10.1002/pds.2319
28. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-20.
29. Platt R, Carnahan RM, Brown JS, Chrischilles E, Curtis LH, Hennessy S, et al. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:1-8. doi:10.1002/pds.2343
30. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, et al; ATRIA Study Investigators. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009;119:1363-9. doi: 10.1161/CIRCULATIONAHA.108.816082
31. Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: The ATRIA study stroke risk score. J Am Heart Assoc. 2013;2:e000250. doi:10.1161/JAHA.113.000250
32. Cutrona SL, Toh S, Iyer A, Foy S, Daniel GW, Nair VP, et al. Validation of acute myocardial infarction in the Food and Drug Administration's Mini-Sentinel program. Pharmacoepidemiol Drug Saf. 2013;22:40-54. doi:10.1002/pds.3310
33. Gagne JJ, Glynn RJ, Rassen JA, Walker AM, Daniel GW, Sridhar G, et al. Active safety monitoring of newly marketed medications in a distributed data network: Application of a semi-Automated monitoring system. Clin Pharmacol Ther. 2012;92:80-6. doi:10.1038/clpt.2011.369
34. Rassen JA, Doherty M, Huang W, Schneeweiss S. Pharmacoepidemiology Toolbox. 2012. Accessed at www.drugepi.org/dope-downloads/#Pharmacoepidemiology Toolbox on 6 October 2017.
35. Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-To-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 2:69-80. doi:10.1002/pds.3263
36. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38:1228-34.
37. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399-424.
38. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-Term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363-72. doi:10.1161/CIRCULATIONAHA.110.004747
39. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125:669-76. doi:10.1161/CIRCULATION AHA.111.055970
40. Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015;131:972-9. doi:10.1161/CIRCULATIONAHA.114.014113